EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder
The plan to file Lentiglobin for sickle cell disease next year gets the green light, as a patient death is deemed unrelated to treatment.
Asco 2020 movers – cell therapy companies dominate the risers
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Asco 2020 – after Tecentriq’s liver win the spotlight falls on Merck and Astra
Roche secures a front-line liver cancer label, but rival data at Asco show that the competition isn’t resting on its laurels.
Asco 2020 – Enhertu impresses, but can it live up to high hopes?
As three Asco presentations confirm the Her2-targeting agent's potency, Daiichi Sankyo and Astrazeneca lay out an ambitious development programme.
Asco 2020 – J&J sees multiple myeloma responses deepen
In anti-BCMA therapy Johnson & Johnson looks to have upstaged Bristol Myers Squibb again, and both companies have backups.
Asco 2020 – Keytruda a “new standard” in biomarker-driven cancer
The Merck & Co drug looks to extend its position in a biomarker-defined colorectal cancer niche, but is it too early to declare victory?
Asco 2020 – Bavencio “cure” suggests another cancer target for immunotherapy
The Merck KGaA/Pfizer drug is said to have cured 52% of women with a rare gynaecological cancer, one of whom subsequently gave birth.
Asco 2020 – Tagrisso shows what early targeting can do
With an 83% reduction in the risk of disease recurrence in early-stage lung cancer, Astrazeneca’s Tagrisso takes the top spot at Asco.
EAN 2020 – Atara’s multiple sclerosis plan slowly takes shape
Two progressive multiple sclerosis subjects in a high-dose six-patient cohort given ATA188 have seen their disease reverse.
